RNU6-162P

Across TCGA pan-cancer cohorts, RNU6-162P RNA is linked to patient survival in 6 of 34 cancer types, making it the most broadly survival-associated RNU6-162P data layer.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher RNU6-162P RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RNU6-162P expression acts as an unfavorable survival marker.

PAAD, PCPG, and ESCA are the cancer types where RNU6-162P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Tertile	All	0.100	0.590	<.001	63	view →
PCPG	DFS	Tertile	All	0.063	0.924	<.001	18	view →
ESCA	DFS	Tertile	All	0.148	0.673	.040	18	view →
SKCM	DFS	Tertile	IV	0.040	0.454	.028	18	view →
KIRC	DFS	Tertile	All	0.188	0.796	.003	18	view →
LUSC	DFS	Tertile	All	0.136	0.791	.005	9	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RNU6-162P–PAAD (OS)

Open the PAAD breakdown →